1. Home
  2. BOLD vs FORA Comparison

BOLD vs FORA Comparison

Compare BOLD & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • FORA
  • Stock Information
  • Founded
  • BOLD 2018
  • FORA 2014
  • Country
  • BOLD United States
  • FORA United States
  • Employees
  • BOLD N/A
  • FORA N/A
  • Industry
  • BOLD
  • FORA Computer Software: Prepackaged Software
  • Sector
  • BOLD
  • FORA Technology
  • Exchange
  • BOLD Nasdaq
  • FORA Nasdaq
  • Market Cap
  • BOLD 54.9M
  • FORA 63.3M
  • IPO Year
  • BOLD 2024
  • FORA N/A
  • Fundamental
  • Price
  • BOLD $2.65
  • FORA $2.09
  • Analyst Decision
  • BOLD Buy
  • FORA Strong Buy
  • Analyst Count
  • BOLD 3
  • FORA 1
  • Target Price
  • BOLD $22.50
  • FORA $5.00
  • AVG Volume (30 Days)
  • BOLD 143.3K
  • FORA 14.7K
  • Earning Date
  • BOLD 11-07-2024
  • FORA 11-13-2024
  • Dividend Yield
  • BOLD N/A
  • FORA N/A
  • EPS Growth
  • BOLD N/A
  • FORA N/A
  • EPS
  • BOLD N/A
  • FORA N/A
  • Revenue
  • BOLD N/A
  • FORA $19,709,723.00
  • Revenue This Year
  • BOLD N/A
  • FORA N/A
  • Revenue Next Year
  • BOLD N/A
  • FORA $13.59
  • P/E Ratio
  • BOLD N/A
  • FORA N/A
  • Revenue Growth
  • BOLD N/A
  • FORA N/A
  • 52 Week Low
  • BOLD $2.33
  • FORA $1.97
  • 52 Week High
  • BOLD $15.24
  • FORA $4.15
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • FORA 53.37
  • Support Level
  • BOLD N/A
  • FORA $1.97
  • Resistance Level
  • BOLD N/A
  • FORA $2.12
  • Average True Range (ATR)
  • BOLD 0.00
  • FORA 0.06
  • MACD
  • BOLD 0.00
  • FORA 0.01
  • Stochastic Oscillator
  • BOLD 0.00
  • FORA 80.00

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About FORA Forian Inc.

Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.

Share on Social Networks: